

# Perioperative outcomes of transurethral resection, open prostatectomy and laser therapy in the surgical treatment of benign prostatic obstruction: a “real world” data analysis of the German D.V.P.Z.\* from 2005-2017 with 10,420 patients



\*D.V.P.Z. = Dachverband der Prostatazentren Deutschlands e.V. (Governing Body of German Prostate Centers)

Herden J.<sup>1</sup>, Ebert T.<sup>2</sup>, Schlager D.<sup>3</sup>, Diederichs W.<sup>4</sup>, Zumbé J.<sup>5</sup>, Sommerfeld H.J.<sup>6</sup>, Schafhauser W.<sup>7</sup>, Kriegmair M.<sup>8</sup>, Garcia Schürmann M.<sup>9</sup>, Distler F.<sup>10</sup>, Baur H.<sup>11</sup>, Oberpenning F.<sup>12</sup>, Reimann M.<sup>13</sup>, Haupt G.<sup>14</sup>, Hoefner K.<sup>15</sup>, Laabs S.<sup>16</sup>, Planz B.<sup>17</sup>, Gronau E.<sup>18</sup>, Platz G.<sup>19</sup>, Buse S.<sup>20</sup>, Jones J.<sup>21</sup>, Heidenreich A.<sup>1</sup>, Ruebben H.<sup>22</sup>, Schultze-Seemann W.<sup>3</sup>, Weib P.<sup>23</sup>

**Objectives:** To compare length of hospital stay, transfusion rates, and re-intervention rates for transurethral resection of the prostate (TUR-P), open prostatectomy (OP), and laser therapy (LT) used for surgical treatment of benign prostatic obstruction (BPO).

**Materials & methods:** The D.V.P.Z. is an organization, in which clinical data of prostatic diseases from 2 university clinics, 19 treatment clinics, 3 private clinics and 270 office-based urologists are collected in order to document the quality and type of cross-sectoral and interdisciplinary treatment. Data on diagnostics, therapy and course of disease are recorded web-based. The analysis includes datasets from 2005-2017.

	TUR-P	OP	LT	
n	8,389	1,334	697	
	Median (IQR)	Median (IQR)	Median (IQR)	p-value
Age (years)	72 (65-77)	72 (66-77)	73 (66-77)	0,032
PSA (ng/ml)	3.3 (1.6-3.3)	5.9 (3.3-5.9)	2.7 (1.2-5.1)	<0,001
Prostatevolume (ml)	45 (32-96)	87 (62-110)	45,5(33-63)	<0,001
IPSS-S	19 (13-19)	19 (14-19)	19 (13-25)	0,684
IPSS-L	4 (3-5)	4 (3-5)	4 (3-5)	0,123

Tab.1: Patients characteristics for TUR-Prostate (TUR-P), open prostatectomy (OP), and laser therapy (LT)

**Results:** Of 10,420 patients, 8,389 (80.5%) were treated with TUR-P, 1,334 (12.8%) with OP, and 697 (6.7%) with LT. Patients characteristics are shown in Tab.1 Median length of hospital stay was 6 days (IQR: 4-7) for TUR-P, 9 days (IQR: 7-11) for OP, and 5 days (IQR: 4-6) for LT (p<0.001) (Fig.1) Transfusion- and Re-Intervention rates are shown in Fig.2. OP had a significantly higher risk for transfusions than TUR-P (OR: 2.44; 95% CI 1.74-3.41; p<0.001) and LT (OR: 3.32; 95% CI 1.56-7.01; p<0.001). Transfusion rates were not significantly different between TUR-P versus LT (OR: 1.36; 95% CI 0.66-2.79; p=0.51). Risk for a hospital stay ≥7 days was higher for OP versus TUR-P (OR: 7.25; 95% CI 6.27-8.36; p<0.001) and LT (OR: 17.89; 95% CI 14.12-22.65; p<0.001); and higher for TUR-P versus LT (OR: 2.47; 95% CI 2.03-3.01; p<0.001). No differences were seen in re-intervention rates between TUR-P versus OP (OR: 1.14; 95% CI 0.88-1.48; p=0.34) and LT (OR: 1.39; 95% CI 0.96-2.02; p=0.8), and between OP versus LT (OR: 1.22; 95% CI 0.79-1.89; p=0.39).





Fig.2: Transfusion- and Re-intervention rates.




Fig.1: Days of hospitalization (Median, IQR, Min, Max)

### Conclusions:

- The D.V.P.Z. database provides health service research data on the surgical treatment of BPO.
- OP was associated with higher transfusion rates and longer hospital stay than TUR-P and LT.
- Risk of transfusion was not different between TURP and LT, but TUR-P was inferior to LT concerning length of hospital stay.
- Re-intervention rates did not differ between the groups.

<sup>1</sup>Prostatecenter Cologne University Hospital, Cologne, Germany, <sup>2</sup>Prostatecenter Metropolregion Nuremberg, Fuerth, Germany, <sup>3</sup>Prostatecenter Freiburg, Freiburg, Germany, <sup>4</sup>Prostatecenter Berlin, Berlin, Germany, <sup>5</sup>Prostatecenter Leverkusen, Leverkusen, Germany, <sup>6</sup>Prostatecenter Marl, Marl, Germany, <sup>7</sup>Prostatecenter Hochfranken-Fichtelgebirge, Marktredwitz, Germany, <sup>8</sup>Urology Center Munich, Planegg, Germany, <sup>9</sup>Prostatecenter Niederrhein, Wesel, Germany, <sup>10</sup>Prostatecenter Nuremberg-Middle Franconia, Nuremberg, Germany, <sup>11</sup>Prostatecenter Nymphenburg, Munich, Germany, <sup>12</sup>Prostatecenter Bocholt, Bocholt, Germany, <sup>13</sup>Prostatecenter Moers, Moers, Germany, <sup>14</sup>Prostatecenter Speyer, Speyer, Germany, <sup>15</sup>Prostatecenter Rhine-Ruhr, Oberhausen, Germany, <sup>16</sup>Prostatecenter Elbe-Weser, Stade, Germany, <sup>17</sup>Prostatecenter Emscher-Lippe, Gladbeck, Germany, <sup>18</sup>Prostatecenter Muensterland, Muenster, Germany, <sup>19</sup>Prostatecenter Mainspitze, Ruesselsheim, Germany, <sup>20</sup>Prostatecenter Alfred Krupp-Hospital, Essen, Germany, <sup>21</sup>Prostatecenter Hochtaunus, Bad Homburg, Germany, <sup>22</sup>Dachverband der Prostatazentren Deutschlands, Berlin, Germany, <sup>23</sup>Prostatecenter Siegen-Wetzlar, Siegen, Germany